Establishing a context of use for three-dimensional cardiac tissue derived from human-induced pluripotent stem cell-derived cardiomyocytes using inotropes.

Yoshiko Okai¹, Emily Pfeiffer Kaushik², Tomoya Sameshima¹, Nicole Feric³, Rishabh Singh³, Isabella Pallotta³, Danielle R Bogdanowicz³, Marietta M Gustilo³, Kosuke Harada¹, Kevin S Baker², Tadahiro Shinozawa¹

¹Drug Safety Research and Evaluation, Takeda Pharmaceutical Company Limited, Kanagawa 251-8555, Japan.

²Drug Safety Research and Evaluation, Takeda Development Center Americas, Inc, Cambridge, MA 02139, United States.

³Valo Health, Inc, New York, NY 10016, United States.

PubMed PMC DOI PDF

Abstract

Safety attrition due to drug-induced inotropic changes remains a significant risk factor for drug development. Mitigating these events during early screening remains challenging. Several in vitro predictive models have been developed to address these issues, with varying success in detecting drug-induced inotropic changes. In this study, we compared traditional two-dimensional human-induced plurip…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.